Enavate Sciences
2 rounds tracked since 5 November 2025.
- Rounds
- 2
- Led
- 0
- Capital in these rounds
- $385M
Sectors
Countries
Rounds
- AirNexis TherapeuticsDevelops dual PDE3/4 inhibitor AN01 for COPD, licensed from Haisco $200MSeries A · 9 Jan
- Braveheart BioCardiac myosin inhibitor BHB-1893 for hypertrophic cardiomyopathy, licensed from Hengrui $185MSeries A · 5 Nov
No round matches these filters.